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The nitric oxide donor nitroprusside intraperitoneally affects perito-
neal permeability in CAPD Nitroprusside is a nitric oxide (NO) donor. To
investigate effects of nitroprusside i.p. on peritoneal permeability and
perfusion, standard peritoneal permeability analyses were performed. Ten
stable CAPD patients were studied twice within one week with glucose
based dialysate (1.36% Dianeal®) with and without addition of nitroprus-
side 4.5 mg/liter. Mass transfer area coefficients (MTAC) of CO2 were
calculated to estimate peritoneal blood flow. Nitrate, a stable metabolite
of NO, and cGMP, a second messenger of NO synthesis, were measured
in plasma and dialysate. The MTACs of low molecular weight solutes were
greater with nitroprusside (NP) compared to the control dwell (C):
creatinine median 14.1 (NP) versus 9.9 mI/mm (C), urea 21.7 (NP) versus
18.5 mI/mm (C) and urate 10.5 (NP) versus 8.6 mI/mm (C) (P < 0.05 for
all). This points to an increased effective peritoneal surface area with
nitroprusside. Furthermore, the restriction coefficient for the low mole-
cular weight solutes decreased from 1.28 (C) to 1.23 (NP) (P = 0.02),
suggesting some effect also on the size selectivity to these solutes. The
effect of nitroprusside on the clearances of serum proteins was more
pronounced. The increase with nitroprusside was 34% for 2-microglobu-
lin, 70% for albumin, 77% for IgG and 143% for a2-macroglobulin. This
reduction in size selectivity was reflected in a decrease in the restriction
coefficient for macromolecules from 2.29 (C) to 1.86 (NP), P < 0.01. This
implies an increase in the intrinsic permeability of the peritoneal mem-
brane. Kinetic modeling, using computer simulations, was done to analyze
these effects in terms of the pore theory, using a convection model and a
diffusion model for the transport of macromolecules. Nitroprusside led to
an increase of both the large pore radius and the small pore radius and of
the unrestricted area over diffusion distance. These effects were more
pronounced with the diffusion model. The MTAC CO2 was not different:
NP 76.9 and C 84.1 mI/mm. MTACs of nitrate were not greater than
expected on the basis of the molecular weight during both dwells. The
dialysate/plasma (D/P) ratio of cGMP was greater after addition of
nitroprusside: 0.36, range 0.21 to 0.77 (C) and 0.74, 0.23 to 2.50 (NP), P =
0.02. With nitroprusside the D/P ratio of cGMP was greater than expected
on the basis of its molecular weight (P < 0.001). This points to local
generation of cGMP after the addition of nitroprusside, induced by NO.
No differences were found in the dialysate concentrations of the prosta-
glandins (PU) PGE2 and 6-keto-PGF1,, and thromboxane B2 after addi-
tion of nitroprusside. The transcapillary ultrafiltration rate and the net
ultrafiltration rate during four hours were not different with nitroprusside.
In conclusion, nitroprusside i.p. increased the effective peritoneal surface
area and the intrinsic permeability, hut the peritoneal blood flow did not
change. The greater than expected D/P ratios of cGMP point to local
generation of cGMP with nitroprusside, induced by NO.
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The amount of a solute that can pass the peritoneal membrane
during peritoneal dialysis is dependent on the effective peritoneal
surface area and the intrinsic permeability of the membrane to
that solute. The effective peritoneal surface area is mainly deter-
mined by the number of perfused peritoneal capillaries [1, 2].
Therefore, this membrane parameter can be influenced by vaso-
active substances. Exposure of animal peritoneal tissues to the
vasodilator nitroprusside causes opening of previously not per-
fused capillaries and increases the capillary pore area [2, 3]. These
effects can be expected to lead to an increase of the effective
peritoneal surface area during peritoneal dialysis, functionally
represented by the MTACs of low molecular weight solutes [4].
Nitroprusside is a nitric oxide donor. The nitric oxide induced
vascular smooth muscle relaxation is mediated by synthesis of
cyclic guanosine monophosphate (cGMP) [5]. Nitric oxide under-
goes oxidative degradation to the stable inorganic nitrogen oxides
nitrite and nitrate. Circulating nitrite reacts rapidly with oxyhe-
moglobin [6], resulting in stoichiometric formation of methemo-
globin and nitrate. Therefore, nitric oxide synthesis is detected in
serum or urine as nitrate [7]. The oxidation of nitric oxide to
nitrite and nitrate takes place within a few seconds [8]. These
findings imply that concentrations of cGMP, nitrite and nitrate
could potentially reflect nitric oxide activity. We previously found
evidence that dialysate concentrations of nitrate in stable CAPD
patients were in accordance with transport of nitrate from the
circulation to the dialysate [9], providing no positive evidence that
nitric oxide would be involved in the regulation of the permeabi-
lity parameters of the peritoneal membrane. However, during
bacterial peritonitis, a situation with a marked increase in perito-
neal surface area [10] and intrinsic permeability [ii], due to the
inflammatory reaction, dialysate over plasma ratios of nitrate
often exceeded 1.0, suggesting local generation of nitric oxide [9].
The aim of the present study was to investigate a possible role
of nitric oxide in the regulation of the peritoneal permeability
characteristics. Therefore, nitroprusside was added to the dialysis
solution during four-hour dwells. Effects on solute transport,
peritoneal blood flow and fluid kinetics were studied. The contri-
bution of nitric oxide was investigated by analysis of nitrite, nitrate
and cGMP concentrations in plasma and dialysate.
Methods
Patients
Two standard peritoneal permeability analyses (SPA) were
performed within one week in ten stable CAPD patients (5
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female/5 male) [121. Their mean age was 43 years (range 19 to 59
years). They were treated with CAPD for 3 to 47 months (median
13 months). The causes for renal replacement therapy were
diabetic nephropathy [3], chronic glomerulonephritis [3], hyper-
tensive nephropathy [11, polycystic kidney disease [11, chronic
pyelonephritis [11 and bilateral Wilms' tumor [1]. All patients
performed CAPD using commercially available dialysate (Dia-
neal®; Baxter By, Utrecht, The Netherlands) and were free of
peritonitis at the time of the study and in the four preceding
weeks. Informed consent was obtained from all patients after an
explanation of the aim and methods of the study. The protocol
was approved by the Committee of Medical Ethics of the Univer-
sity Hospital of Amsterdam.
Study design
The SPAs were performed while the patients were sitting in a
comfortable chair during four-hour dwell periods. Both tests were
done with 1.36% glucose dialysate (Dianeal®), one day with and
the other day without the addition of 4.5 mg/liter sodium nitro-
prusside. Dextran 70 (Macrodex®, NPBI, Emmercompascuum,
The Netherlands) 1 g/liter was added for the measurement of
peritoneal fluid kinetics [13]. The sequence of both experiments
was randomized. The peritoneal cavity was rinsed with 1.36%
glucose dialysate before instillation of the test solution into the
abdomen. On the nitroprusside day, 4.5 mg/liter nitroprusside was
also added to the rinsing bag. Before inflow and 10, 20, 30, 60, 120,
180 and 240 minutes after instillation of the test solution samples
were taken from the dialysate. To avoid the effect of dead space,
the samples were collected after a temporal drainage of 100 to 200
ml. After drainage of the test solution, the abdomen was rinsed
again with 1.36% glucose dialysate. For the calculation of the
residual volume, samples were collected from this rinsing bag.
Blood samples were taken before and after the test. Dextran 1 (20
ml, Promiten®, NPBI) was given intravenously after the first
blood sample to prevent possible anphylaxis to dextran 70 [14].
Sodium hydroxide (0.1 mol/liter) was added to both the rinsing
bag and the test bag (5 mI/liter) to increase the pH in order to
avoid local generation of carbon dioxide gas from diffused bicar-
bonate [15]. Blood pressure was measured before inflow of the
first rinsing bag, during outflow of the rinsing bag and 10, 30 and
60 minutes after instillation of the test solution.
The MTAC of carbon dioxide gas (CO2) may be considered an
estimate of peritoneal blood flow [15—171 because it is a small
molecule, which diffuses rapidly from the blood to the dialysate. It
can be calculated from the PCO2 in the dialysate and the PCO2 in
an arterialized blood sample. To obtain the latter, the hand of the
patient was placed in a thermoregulated plexiglass box at 60°C.
After 15 minutes, arterialized venous blood samples for CO7
determination were taken from the hand veins in a retrograde
direction [18, 19]. It has been shown that with this method arterial
PCO2 can be estimated accurately from the values of arterialized
venous blood [19].
Measurements
Total dextran 70 was determined in all dialysate samples by
means of high performance liquid chromatography [20]. Both in
plasma and dialysate urea, creatinine and urate were measured by
enzymatic methods (Boehringer Mannheim, Mannheim, Germa-
ny). Beta-2-microglobulin was determined on an IMx system using
a Microparticle Enzyme Immunoassay (Abbott Laboratories,
North Chicago, IL, USA). Albumin, IgG and a2-macroglobulin
were measured by nephelometry (BN100; Behring, Marburg,
Germany). Glucose was measured by the glucose oxidase-perox-
idase method using an autoanalyzer (SMA-TI; Technicon, Terry-
town, USA). Blood and dialysate for determination of CO2 was
kept on ice after sampling and immediately analyzed by a blood
gas analyzer.
Blood and dialysate samples for nitrite, nitrate and cGMP were
centrifuged at 1530 g for 10 minutes and immediately stored at
—20°C. Nitrite and nitrate were measured by ion-pair high
performance liquid chromatography. The lower detection limit
was 2.5 jmol/liter. cGMP was measured by an Enzyme Immuno-
assay (Cayman Chemical Company, Ann Arbor, MI USA). The
prostaglandins PGE2, 6-keto-PGF1 and thromboxane B2 were
determined in dialysate by radioimmunoassays according to the
method of Thomas et al [21] with one modification previously
described by Zemel et al [11].
Calculations
The MTACs of urea, creatinine, urate and nitrate were calcu-
lated according to the model of Waniewski et al [22], in which the
solute concentration in plasma was expressed per volume of
plasma water [23]. For cGMP, dialysate/plasma (D/P) ratios were
calculated because in two patients the cGMP concentrations in
dialysate were greater than in plasma after the addition of
nitroprusside. Therefore, it was not possible to calculate MTACs.
The MTAC of CO2 was calculated during the first 30 minutes of
the dwell according to the Garred model, using all dialysate
determinations in that period [24]. Peritoneal clearances of
/32-microglobulin, albumin, TgG and a2-macroglobulin were de-
termined using the equation: Cl (1.d/min) = (D V)/(P t), where
Cl is the clearance, D is the dialysate concentration, V is the
dialysate volume, P is the plasma concentration and t is the dwell
time.
The intrinsic permeability of the peritoneal membrane can be
represented by the peritoneal restriction coefficient (RC) [4, 25,
26]. The restriction coefficient is the slope of the linear relation-
ship between the MTACs or clearances of various solutes and
their free diffusion coefficient in water (D20,w) when plotted on a
double logarithmic scale: MTAC or Cl = constant D2OWRC. To
calculate the restriction coefficient for the low molecular weight
solutes the MTACs of urea, creatinine, urate and /32-microglobu-
lin were used. The MTAC for /32-microglobulin was calculated as
its peritoneal clearance. The clearances of the proteins /32-
microglobulin, albumin, IgG and a2-macroglobulin were used to
calculate the restriction coefficient for the peritoneal membrane
to macromolecules.
A regression line was calculated, based on the power relation-
ship between the MTACs or D/P ratios of urea, creatinine, urate
and 132-microglobulin, and their molecular weights. The expected
MTACs of nitrate and D/P ratios of cGMP, if their dialysate
concentrations would only be determined by diffusion from the
circulation, were calculated by interpolation of their molecular
weights on this line. Any differences between observed and
expected MTACs of nitrate and D/P ratios of cGMP were tested
by a modified t-test to analyze whether the deviation from the
regression line was significant. This test takes the variability of the
regression line between molecular weights and MTACs or DIP
ratios into account [27].
The peritoneal fluid parameters were calculated as described
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previously by Imholz et al [26]. Briefly, fluid transport across the
peritoneum during CAPD is influenced by opposing mechanisms.
The transcapillary ultrafiltration increases the intraperitoneal
volume and fluid loss from the peritoneal cavity is assumed to be
by transcapillary back filtration and lymphatic absorption. The
total result of these is the net ultrafiltration. The effective
lymphatic absorption rate can be approximated as the disappear-
ance rate of dextran 70 [28]. These calculations include all
pathways of uptake into the lymphatic system, both subdiaphrag-
matic and interstitial. The transcapillary ultrafiltration was calcu-
lated from the dilution of dextran 70. The transcapillary ultrafil-
tration rate has its maximum value during the initial phase of a
dwell [26, 29 —311. Therefore, the transcapillary ultrafiltration rate
in the first minute was calculated using the Lineweaver-Burke
plot, that is, the linear regression between the reciprocal values of
the transcapillary ultrafiltration obtained during the SPA and the
reciprocal of time [13].
Kinetic modeling, by means of computer simulation, was used
to analyze the effect of nitroprusside in terms of the pore theory,
previously described by Rippe and Stelin [32] and Imholz et a!
[33]. Briefly, solute and fluid transports are assumed to occur
across the peritoneal membrane by three different pores: a large
number of small pores, a small number of large pores, and a set of
ultrasmall pores, which only contribute to fluid transport. This can
be described by two different models, depending on the relative
importance of diffusion or convection in the transport of macro-
molecules across the large pores. In model I a positive hydrostatic
pressure gradient was assumed to be present across the large
pores. Therefore, the transport of macromolecules was deter-
mined by hydrostatic convection, according to the principles of
Rippe and Stelin [32]. The hydrostatic pressure gradient across
the large pores was assumed to approximate 0 mm Hg in model II.
Consequently, the macromolecular transport in that model was
only determined by diffusion. Only in model I, the convection
model, are the large pores involved in fluid transport. In both
models, the pore size and the unrestricted area over diffusion
distance, that is, the surface area available for diffusion divided by
the length of the pathway from the capillary wall to the dialysate,
were varied to obtain the best fit between the estimated and
measured solute clearances. Also, the large to small pore surface
area and the ratio of the large to small pore numbers were
calculated.
Results are given as median values and ranges. Wilcoxon
matched pairs rank sum test and Spearman rank correlation test
were used for distribution free testing.
Results
Transport of low molecular weight solutes and proteins
The 1.36% glucose dialysate with and without nitroprusside was
well tolerated and no side effects were observed. No marked blood
pressure decreases were noted. The MTACs of the low molecular
weight solutes urea, creatinine and urate were significantly greater
during the dwell with nitroprusside (Table 1). The median in-
crease for urea was 13%, for creatinine 43% and for urate 22%.
The restriction coefficient for the low molecular weight solutes
decreased with a median value of 4%. The glucose absorption
during the four-hour dwell increased 11% with nitroprusside
(Table 1). The MTAC of CO2 was not different after addition of
nitroprusside (Table 1). The clearances of 132-microglobulin (mo-
Table 1. MTACs of the low molecular weight solutes, the absorption of
glucose, peritoneal protein clearances, restriction coefficients calculated
on the MTACs of the low molecular weight solutes and the clearances
of the macromolecules, and the albumin loss during the four hour dwell
1.36% Glucose + Nitroprusside P value
MTAC mi/mm
CO2 84.1 (45.4—151.4) 76.9 (44.6—100.1) 0.48
urea 18.5 (13.1—24.3) 21.7 (15.9—27.2) 0.02
creatinine 9.9 (6.4—14.8) 14.1 (9.7—21.3) 0.006
urate 8.6 (5.6—13.4) 10.5 (8.4—14.9) 0.006
Glucose absorption % 63 (44—78) 74 (46—84) 0.006
Clearance p1/mm
/32-microglobulin 993 (474—1817) 1431 (554—2389) 0.006
albumin 97 (71—153) 170 (98—291) 0.006
lgG 58 (38—118) 115 (58—177) 0.006
a2-macroglobulin 19 (7—40) 45 (17—114) 0.01
Restriction coefficient
low molecular weight 1.28 (1.11—1.59) 1.23 (1.05—1.59) 0.02
solutes
macromolecules 2.29 (2.02—2.62) 1.86 (1.56—2.18) 0.008
Albumin loss g/4 hr 0.79 (0.54—1.25) 1.35 (0.73—2.48) 0.006
Values are given as medians with ranges.
lecular wt 11,800 Da), albumin (molecular wt 69,000 Da), IgG
(molecular wt 150,000 Da) and a2-macroglobulin (molecular wt
820,000 Da) were significantly greater with nitroprusside (Table
1). The relative increase in clearances with nitroprusside was
greater, the larger the molecular weight of the proteins: f32-
microglobulin 34%, albumin 70%, IgG 77% and a2-macroglobu-
lin 143%. This resulted in a lower restriction coefficient for
macromolecules with a median decrease of 16%. The albumin loss
during the four-hour dwells increased 69% (range 17% to 199%).
Nitric oxide and prostaglandins
The nitrite concentrations in dialysate were below the lower
detection limit. The MTACs of nitrate were not different with
nitroprusside (Table 2), and were correlated with the MTAC of
creatinine: control r = 0.85, P = 0.01; nitroprusside r = 0.75, P =
0.03. The observed MTACs and DIP ratios of nitrate were not
greater than expected on the basis of its molecular weight (Fig. I
for D/P ratios), and so were not indicative of local generation. The
D/P ratios of cGMP during the control dwell were significantly
lower than expected on the basis of its molecular weight (P <
0.001, Fig. 1). In contrast to nitrate, the increase during nitroprus-
side (median 46%) was greater than expected on the basis of its
molecular weight (P < 0.001, Fig. 1). In two patients the DIP ratio
even exceeded 1.0. This points to the local generation of cGMP
after the addition of nitroprusside, induced by nitric oxide. No
differences were found in the dialysate concentrations of the
prostaglandins PGE2 and 6-keto-PGF1, and thromboxane B2
after addition of nitroprusside (Table 2).
Fluid kinetics
The transcapillary ultrafiltration rate (TCUFR) during a four-
hour dwell was not different after addition of nitroprusside: 1.03
mi/mm, range 0.13 to 2.02 mllmin (control) and 1.23 mI/mm,
range 0.07 to 2.92 ml/min (nitroprusside), P = 0.3 (Fig. 2). The
transcapillary ultrafiltration rate is highest during the initial phase
of a dwell. The TCUFR0 was 1.71 mi/mm (0.57 to 7.73
mi/mm) during the control dwell (P = 0.02 vs. TCUF04 hr) It
1888 Douma et a!: Nitroprusside and peritoneal permeability
Table 2. The MTACs of nitrate (mi/mm), the D/P ratios of eGMP and
the dialysate concentrations (ng/l) of the prostaglandmns PGE2, 6-keto-
PGF1 and thromhoxane B2
1.36% Glucose + Nitroprusside P value
MTAC nitrate 9.5 (5.7—13.9) 10.3 (5.8—22.4) 0.15
D/P cGMP 0.36 (0.21—0.77) 0.74 (0.23—2.5 1) 0.02
PGE, 171 (84—258) 159 (73—372) 0.68
6-keto-PGF1 34 (0—112) 35 (2—62) 0.54
TxB2 21 (0—31) 25 (0—34) 0.16
Values arc given as medians with ranges.
increased to 4.42 mI/mm (1.36 to 11.81 mi/mm) in the nitroprus-
side experiments (P = 0.009 vs. TCUF0_4 P = 0.06 when
compared to the control experiments. The effective lymphatic
absorption rate was 0.98 mi/mm (0.54 to 1.92 mi/mm) during the
control dwell and 0.90 mI/mm (0.48 to 1.87 mi/mm) with nitro-
prusside, P = 0.02. The resulting net ultrafiltration rate with
nitroprusside during four hours was 0.23 ml/min (—1.07 to 2.10
mi/mm) and 0.03 mI/mm (—1.07 to 0.97 mI/mm) during the
control dwell (P = 0.2).
Three pore models
The measured solute clearances were in good acordanee with
the estimated clearances obtained with the two models. The mean
value of the error between the measured and the estimated
clearances was 7.1%. No differences in the magnitude of the error
was present between the models or between the control and the
nitroprusside experiments. Model I was calculated for nine pa-
tients, because for one patient the transcapillary ultrafiltration
rate was too low (0.07 mI/mm) to use the convection model. With
the application of model I the large pore radius increased 15%
and the small pore radius increased 10% (Table 3). Tn this
convection model the percentage of large pores and also the
fractional large pore surface area were not different with nitro-
prusside. The increase in the unrestricted area over diffusion
distance was 25%.
The large pore size calculated with model 11 was greater
compared to model I during the control studies as well as after
addition of nitroprusside. Using this diffusion model the large
pore radius increased 30% with nitroprusside and the small pore
radius increased 11% (Table 3). The percentage of large pores
was not different. The fractional large pore surface area was larger
with nitroprusside (median 49%). The median increase in the
unrestricted area over diffusion distance was 6% after addition of
nitroprusside.
Discussion
Tntrapcritoneal administration of nitroprusside caused an in-
crease in the MTACs of the low molecular weight solutes and of
serum proteins. This increase was more pronounced the higher
the molecular weight. No change was found in the MTAC of CO2.
These effects will be interpreted in terms of functional alterations
in peritoneal membrane characteristics in the following sections.
The transport of a solute across the peritoneal membrane is
dependent on two permeability characteristics, namely, the effec-
tive surface area of the membrane and the intrinsic permeability
to this solute, that is, the size selectivity [34], This size selectivity
can be expressed as the peritoneal restriction coefficient. When
the restriction coefficient equals 1.0, differences in MTACs of
various solutes are only caused by differences in the free diffusion
coefficients of these solutes. These are dependent on their molec-
ular weights and shapes. We have previously shown that the
restriction coefficient for the transport of low molecular weight
solutes averages 1.2 [26, 35]. This implies that the transport of
small solutes is hardly influenced by the size selectivity of the
peritoneal membrane. Therefore, it is mainly dependent on the
effective peritoneal surface area. Consequently, the nitroprusside
induced rise of the MTACs of the low molecular weight solutes is
caused by an increase in surface area. In addition, the small
decrease in the restriction coefficients also suggested a slight effect
on the size selectivity to these solutes.
Based on animal studies [2, 3] the increase in effective perito-
neal surface area after nitroprusside is likely to be caused by an
increment in the number of newly opened capillaries. This was not
accompanied by a greater peritoneal blood flow, measured as the
MTAC of CO2. Also Grzegorzewska and Antoniewicz found no
difference in the peritoneal transfer of CO2 after intraperitoneal
administration of nitroprusside in intermittent peritoneal dialysis
patients [36]. Two explanations are possible for this finding. First,
the MTAC of CO2 is not a good measurement of peritoneal blood
flow. The method has never been validated in animal studies,
although it is the only method that has been, and can be used in
peritoneal dialysis patients [15]. The most important assumption
is the absence of marked transeellular diffusion of CO2, as this
could influence the estimation of the peritoneal blood flow. We
have previously shown that the MTAC of CO2 was significantly
higher during a dwell with an amino acid based dialysis solution
compared to glucose dialysate without evidence that transcellular
CO2 transport or local CO2 generation would be different during
these dwells [371. This would suggest that the MTAC of CO2 can
be used to detect differences in peritoneal blood flow, although
the interpretation of the absolute values remains uncertain.
Second, the peritoneal blood flow is indeed not influenced by
nitroprusside. Blood flow is dependent on the arteriolar minus
venous pressure gradient divided by the vascular resistance. The
regulation of capillary hydrostatic pressure in peripheral capillary
beds is mainly at the level of the precapillary sphincters. In
contrast, the resistance at the venous end is not well regulated and
dependent on the general venous pressure. As a consequence,
intraperitoneal nitroprusside could decrease the capillary hydro-
static pressure gradient by its local effect in the precapillary
sphincter without an effect on the pressure at the venous side
because it exerts no systemic effects on portal or caval pressure.
This is in accordance with the finding in this study and by others
that the blood pressure was not influenced by the intraperitoneal
administration of nitroprusside. The unchanged peritoncal blood
flow suggests that the decrease in the capillary hydrostatic pres-
sure gradient is proportional to the decrease in peritoneal vascu-
lar resistance caused by the increase in the number of perfused
peritoneal capillaries. The effects of nitroprusside on the MTACs
of low molecular weight solutes despite unaltered blood flow can
be explained by the observation that the spianchnic blood volume
is much more important than blood flow for the solute transfer
rates [381.
The effect of nitroprusside on the transport of macromolecules
was greater for larger proteins and varied from 34% increase for
132-microglobulin to 143% for a2-macroglobulin. This reduction
in size selectivity was reflected in a decrease in the restriction
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Fig. 1. Regression lines based upon the
relationship between DIP ratios of urea,
creatinine, urate and 132-microglobulin and their
molecular weights. The D/P ratios of nitrate and
cGMP are given in relation to their molecular
weights, in the left panel with 1.36% glucose
and in the right panel after addition of 4.5 mgI
liter nitroprusside. The D/P ratios of nitrate
were lower than expected on the basis of the
molecular weight (P < 0.001). With
nitroprusside the D/P ratio of cGMP was above
the transport line, suggesting local production.
10203060 120 180 240 10203060 120 180 240
Time, minutes Time, minutes
Fig. 2. The time course of the transcapillaiy ultrafiltration (U), lymphatic absorption (V) and the resulting change in intraperitoneal volume (A) with 1.36%
glucose dialysate (A) and after the addition of nitroprusside (B). p < 0.05 when compared to the glucose solution without nitroprusside.
Table 3. Peritoneal membrane characteristics (median and ranges) after fitting the measured solute clearances with model I (convection through
large pores only) and model II (diffusion through large pores only)
Model I Model II
1.36% Glucose + Nitroprusside 1.36% Glucose + Nitroprusside
Small pore radius A
Large pore radius A
47
143
(41—58)
(116—157)
51
155
(4471)a
(135_187)a
45
490
(40—54)
(250—700)
51
700
(41_64)h
(380_looo)h
% Large pores 0.08 (0.05—0.16) 0.07 (0.05—0.14) 0.22 (0.05—1.10) 0.20 (0.05—0.98)
Fractional large pore
Surface area % 0.69 (0.54—0.94) 0.63 (0.52—0.89) 24.8 (10.9—39.0) 35.2 (13.2—68.2)
Unrestricted area over
Diffusion distance in 143.5 (114.0—223.0) 180.0 (150.0—275.0) 115.8 (68.0—199.0) 133.5 (90.O—205.0)
a p < 0.05, h p  0.01 versus 1.36% glucose dialysate without nitroprusside
coefficient for macromolecules. This implies that the intrinsic
permeability of the peritoneal membrane increased.
How can these effects be explained in terms of the pore theory?
The peritoneal membrane contains many small pores that are
involved in the transport of low molecular weight solutes. The
interendothelial clefts are probably the anatomic equivalents of
these small pores. Only a few large pores for transport of
macromolecules are assumed to be present. Veriular interendo-
thelial gaps as can be provoked by the administration of some
vasoactive substances may he the anatomic equivalents of the
large pores [39]. This had been made likely for histamine by the
groups of Fox [391 and Miller [401. Fox et al [39], who studied the
permeability of the microvasculature of the cat and rat mesentery
by in vivo microscopy, found extravasation of fluorescent serum
albumin in response to locally administered histamine. Electron
microscopy of the vessels where extravasation was seen, showed
gaps in the endothelium. These effects were only found in venules
and small veins, and not in arteries, arterioles or capillaries. Miller
et al [40] investigated drug induced protein leakage from the rat
cremaster muscle also using in vivo microscopy. These authors
found that both nitroprusside and histamine produced protein
leakage and vasodilation, although the maximal effect on protein
leakage was less with nitroprussside than that observed with
histamine, and it occurred at concentrations higher than those
needed to produce substantial dilation. No effect on protein
permeability was present using the vasodilator isoproterenol.
Recently, Addicks et al [41] reported that intravascular adminis-
tration of nitric oxide donors did not have the potency to increase
a-
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microvascular permeability of an isolated perfused rat mesentery
model. These contrasting findings can, however, be explained by
the different administration route, the fact that much lower
dosages were used, and that the animals were not alive during
these experiments.
Using model 1, based on convection through large pores only,
the pore sizes during the control dwell were in accordance with
the results of Imholz et al [33], who found a average large pore
radius of 184 A and a small pore radius of 48 A, and of Rippe and
Stelin [32], who found a large pores radius between 200 and 300
A and a small pores radius between 40 and 55 A. Comparing
model I and model II, there is a marked difference in the large
pore radius (about 340%), the number of large pores (0.08% vs.
0.22%), and consequently in the fractional large pore surface area
(0.69% vs. 24.8%). These differences between the 'convection
model' and the 'diffusion model' were also described by Imholz et
al [331, who found these differences even more pronounced.
Irrespective of the models used, the radii of the large pores and
the small pores were significantly increased with nitroprusside.
Opening the previously not perfused capillaries by nitroprusside
[2] will increase the total number of pores, hut there is no reason
to assume that the distribution of the pore sizes will be different in
these newly opened capillaries. This corresponds with our obser-
vation that the percentage of large pores did not change with
nitroprusside. The increase in pore radius of the large pores was
more pronounced than the increase in the radius of the small
pores, resulting in an increase in the fractional large pore surface
area. This increase was only found with model II. These observa-
tions are in accordance with expectations based on the anatomical
equivalents of the pores. It is unlikely that the radius of an
interendothelial cleft (small pore) can increase very much. In
contrast, the radii of the venular interendothelial gaps (large
pores) are probably more dynamic structures and can be influ-
enced by vasoactive substances to a larger extent. The unrestricted
area over diffusion distance increased with nitroprusside. This is in
accordance with the greater MTACs of the low molecular weight
solutes, which are used as a representation of the effective
peritoneal surface area. The slight decrease in the restriction
coefficient for the low molecular weight solutes is likely to be
caused by the small increase in the small pore radius found by
both models. The decrease in the restriction coefficient for
macromolecules reflects the increased large pore radius.
The vasodilating effect of nitroprusside is based on the donation
of nitric oxide. The nitrite concentrations in the dialysate were
below the lower detection limit, both during the control dwell and
after addition of nitroprusside. Two explanations are possible:
first, the nitric oxide effect of intraperitoneal administrated nitro-
prusside is not reflected in increased nitrite concentrations in
dialysate, or second, the nitrite generated by nitric oxide is
immediately oxidized to nitrate, as occurs in the circulation. To
distinguish between both alternatives, we tested the stabilty of the
addition of nitrite in different kinds of dialysate. Both fresh
dialysate and spent dialysate were used. There was no evidence
for formation of nitrate from nitrite after incubation for four
hours at 37°C. This suggests that the nitric oxide derived from
nitroprusside is transported to the circulation by diffusion. The
nitrite, generated by nitric oxide, will then react with oxyhemo-
globin to form methemoglobin and nitrate [7]. The concentrations
of nitrate in the dialysate are therefore likely to be determined by
diffusion from the circulation. This is supported by the correlation
between the MTAC of nitrate and the MTAC of creatinine, both
in the presence and absence of nitroprusside. The actions of nitric
oxide are mediated by the activation of soluble guanylate cyclase,
resulting in enhanced synthesis of eGMP [42]. After the addition
of nitroprusside, in two patients the dialysate concentration of
cGMP exceeded the plasma concentration. This can only be
explained by local generation of eGMP in the peritoneal cavity by
nitric oxide, and this was confirmed by the finding that with
nitroprusside, the DIP ratio of cGMP was greater than expected
on the basis of its molecular weight. During peritonitis, which is
also a situation with vasodilation, elevated dialysate concentra-
tions of the prostaglandins PGE2, 6-keto-PGF1, PGF2 and
thromboxane B2 have been reported [11, 43]. In the present study
we found no differences in the dialysate concentrations of PGE2,
6-keto-PGF1 and thromboxane B2. It is likely that these prosta-
glandins are not involved in the nitric oxide induced vasodilation
during stable CAPD with nitroprusside.
The transcapillary ultrafiltration rate is highest during the initial
phase of a dwell. After the addition of nitroprusside the difference
in transcapillary ultrafiltration rate between the first minute and a
four-hour dwell was even larger. The effects of nitroprusside on
transcapillary fluid transport were most pronounced in the first
minutes of the dwell. After four hours the differences had
disappeared. This can be explained by the opposing effect of a
large effective peritoneal surface area on ultrafiltration. It allows
high water transport due to the large area available for transport.
This is especially the case in the initial phase of a dwell. However,
this effect is opposed by an increased absorption of glucose
leading to a rapid disappearance of the osmotic gradient. The
lymphatic absorption rate was lower with nitroprusside. The
resulting overall effect on net ultrafiltration after four hours was
not different between the nitroprusside and the control experi-
ments. This is in accordance with the findings of Miller et al [44],
who added nitroprusside to the dialysate during a 30-minute dwell
period and found no difference in drainage volume. Also, in
studies with rats the net ultrafiltration per exchange did not
change after the addition of nitroprusside to the dialysate [45].
Loss of ultrafiltration is a well known complication in patients
undergoing long-term peritoneal dialysis [46, 47]. The transcapil-
lary ultrafiltration rate increased with nitroprusside during the
initial phase of the dwell, but this positive effect was counteracted
by the increased glucose absorption rate. It suggests that nitro-
prusside can augment ultrafiltration during CAPD when osmotic
agents are employed that are absorbed to a lesser degree than
glucose. The absorption rate of ieodextrin, a large molecular
weight glucose polymer fraction averages 20% [48]. Therefore, it
can be expected that the combination of icodextrin based dialysate
with nitroprusside will also increase ultrafiltration during long
dwells, This hypothesis is currently under investigation.
It can be concluded that nitroprusside intraperitoneally caused
an increase of the effective peritoneal surface area and the
intrinsic permeability to macromolecules. These effects were more
pronounced for larger molecules. Using kinetic modeling the
observed phenomena were likely to be caused by an increase in
the number of pores in combination with a slight increase in the
small pore radius and a much larger increase in the average large
pore radius. The higher than expected DIP ratios of cGMP point
to local generation of cGMP after the adition of nitroprusside,
induced by nitric oxide. It suggests that DIP ratios of cGMP may
reflect local effects of nitric oxide during peritoneal dialysis.
Douma et al: Nitropntsside and peritoneal permeability 1891
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